eGenesis: Pig Organs Edited for Human Transplant
eGenesis edits pig genomes across three targets to make organs humans can accept — the kidney has reached a living patient, but most of the pipeline is still preclinical and independent replication is thin.
Five-year mortality on dialysis is 50%. Transplantation is the gold standard, but donor organs are chronically scarce.
eGenesis (founded 2015, $454M raised) edits pig genomes so their organs become viable for human transplant — replacing the organ source, not refining the dialysis machine.
Three editing targets. Knock out pig antigens — reducing the risk of rejection. Insert human transgenes — reducing immunologic and physiologic incompatibility between the graft and recipient. Inactivate porcine endogenous retroviruses (PERVs) — insurance against infection in an immunosuppressed patient.
The kidney program is furthest along. EGEN-2784 received FDA IND clearance for clinical trials spanning Phases 1 through 3, and the company announced the first transplant of an engineered porcine kidney into a living patient. Heart is preclinical in baboons: 8 of 15 survived past one month, 6 past three, the longest past 24 months. Liver: available data describes extracorporeal cross-circulation with transgenic pig livers in brain-dead decedents; we found no company-specific results for living patients.
Of 33 checkable company claims, all 33 confirmed (2 unverifiable excluded). Independent replication scores 5/10: outside groups have not yet reproduced eGenesis results with durable outcomes. The 54.69/100 rating reflects the stage, not the idea.
If the transplanted kidney holds up in clinical trials, it creates a scalable organ source independent of human donors. Heart and liver use the same platform but lag significantly in stage.
Next post: the team behind eGenesis.
Company profile on Eternal Search
eGenesis is one of very few companies that has transplanted a genome-edited animal organ into a living human; the gap between that fact and the still-early clinical proof is the honest story to tell.